Lung Cancer

PLCOm2012 uses additional parameters to predict the risk of lung cancer and was found more effective when identifying both Indigenous and non-Indigenous individuals with lung cancer.

Pembrolizumab (Keytruda) gains its sixth approval in non–small cell lung cancer (NSCLC), with the latest indication in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a monotherapy for the post-surgical adjuvant treatment of patients with resectable NSCLC.

Mental health treatment may be necessary when SAEs occur.

Trial data bolster the role of nivolumab and nivolumab-based combinations in both early and metastatic stages of multiple cancer types, especially in patient groups with high unmet needs.

Encorafenib (Braftovi; Pfizer Inc) and binimetinib (Mektovi; Pfizer Inc) approved for the treatment of patients with metastatic non-small cell lung cancer who harbor a BRAF V600E mutation.

The MARIPOSA study evaluated amivantamab-vmjw (Rybrevant; Janssen Pharmaceutical) in combination with lazertinib compared to osimertinib and compared to lazertinib monotherapy in the first-line treatment of EGFR-mutated non–small cell lung cancer.

Nivolumab has also demonstrated efficacy in immunotherapy-based combinations for the treatment of certain types of melanoma and bladder cancers.

In many countries, trastuzumab deruxtecan is the only HER2-targeted therapy approved for patients with this HER2–mutant metastatic non-small cell lung cancer.

Moderna has advanced 6 programs into late-stage development, including for respiratory conditions, latent and other viruses, oncology, and rare diseases.

Investigators found an approximately 23% decrease in overall cancer incidence in April 2020, specifically for breast, colon, rectal, head and neck cancers, as well as melanoma and endocrine cancer diagnoses.

Sotorasib (Lumakras) plus carboplatin and pemetrexed shows promise in the first line treatment of advanced non–small cell lung cancer.

Compared to chemotherapy alone, the combined nivolumab and ipilimumab treatment more than tripled the overall survival rate at 6 years in patients with PD-L1 expression <1%.

The study met its primary endpoint of progression-free survival, and overall survival is continuing to be evaluated.

Patients who received amivantamab plus chemotherapy or amivantamab without chemotherapy presented better outcomes compared to chemotherapy alone.

If approved, alectinib would be the only anaplastic lymphoma kinase inhibitor to show reductions in risk of recurrence or death for those with early-stage lung cancer.

Patients with cancer and survivors of cancer that had engaged in administrative tasks to effectively estimate costs or pay for care was associated with an 18% increase in cost-related treatment delays or treatment nonadherence.

The supplemental biologics license application for amivantamab-vmjw (Rybrevant) is supported by data from the phase 3 PAPILLON trial, evaluating the efficacy and safety of the drug in combination with chemotherapy for those with non–small cell lung cancer.

Investigators found that artificial intelligence chatbots did not consistently provide recommendations for cancer treatment that correspond with NCCN guidelines.

The digital cessation platform is the first FDA-cleared OTC device to help individuals quit smoking tobacco.

In the study, investigators incorporated data from electronic health records and social determinants of health into the model to determine the likelihood in delays when starting cancer therapy.

Based on results from a trial of repotrectinib in patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer, the FDA accepted the New Drug Application and set a Prescription Drug User Fee Act goal date of November 27, 2023.

Though an association was found between depression and anxiety and lung cancers, there were no connections found to overall, breast, prostate, colorectal, and alcohol-related cancers.

Amivantamab-vmjw in combination with chemotherapy could assist patients diagnosed with non–small cell lung cancer when chemotherapy alone did not show benefit.

The 5-year survival rate for patients with exon 20 insertion EFGR mutation is 8% in the frontline setting, worse than the survival rate of the 2 most common types of EGFR mutations in patients with advanced or metastatic non-small cell lung cancer.

A panel at the Advanced Topics for Oncology Pharmacy Professionals Summit discusses strategies to address patients’ fears and distrust of the medical and scientific community.